Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $390.2 million.

  • Dexcom's Shares Outstanding (Weighted Average) fell 86.38% to $390.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $390.2 million, marking a year-over-year decrease of 86.38%. This contributed to the annual value of $390.2 million for FY2025, which is 86.38% down from last year.
  • Dexcom's Shares Outstanding (Weighted Average) amounted to $390.2 million in Q4 2025, which was down 86.38% from $391.4 million recorded in Q3 2025.
  • Over the past 5 years, Dexcom's Shares Outstanding (Weighted Average) peaked at $399.2 million during Q2 2024, and registered a low of $96.3 million during Q1 2021.
  • For the 5-year period, Dexcom's Shares Outstanding (Weighted Average) averaged around $375.4 million, with its median value being $389.8 million (2022).
  • In the last 5 years, Dexcom's Shares Outstanding (Weighted Average) surged by 31247.33% in 2021 and then plummeted by 177.86% in 2025.
  • Over the past 5 years, Dexcom's Shares Outstanding (Weighted Average) (Quarter) stood at $386.9 million in 2021, then grew by 0.65% to $389.4 million in 2022, then fell by 0.87% to $386.0 million in 2023, then rose by 1.97% to $393.6 million in 2024, then fell by 0.86% to $390.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $390.2 million for Q4 2025, versus $391.4 million for Q3 2025 and $392.1 million for Q2 2025.